» Articles » PMID: 20038433

Functional Switching of TGF-beta1 Signaling in Liver Cancer Via Epigenetic Modulation of a Single CpG Site in TTP Promoter

Overview
Specialty Gastroenterology
Date 2009 Dec 30
PMID 20038433
Citations 49
Authors
Affiliations
Soon will be listed here.
Abstract

Background & Aims: Acquisition of resistance to the antiproliferative effect of transforming growth factor (TGF)-beta1 is crucial for the malignant progression of cancers. In this study, we sought to determine whether deregulated expression of tristetrapolin (TTP), a negative posttranscriptional regulator of c-Myc, confers resistance to the antiproliferative effects of TGF-beta1 on liver cancer cells.

Methods: The epigenetics of TTP promoter regulation and its effects on TGF-beta1 signaling were examined in hepatocellular carcinoma (HCC) cell lines and patient tissues.

Results: TTP was down-regulated in HCC cell lines (10/11), compared with normal liver, as well as in tumor tissues (19/24) from paired HCC specimens. Methylation of a specific single CpG site located within the TGF-beta1-responsive region (TRR) of the TTP promoter was significantly associated with TTP down-regulation in both HCC cell lines and tumor tissues (r = -0.606383, P < .001). The singly methylated CpG site was specifically bound by a transcriptional repressor complex consisting of MECP2/c-Ski/DNMT3A and abolished the TGF-beta1-induced as well as basal-level expression of TTP. The epigenetic inactivation of TTP led to an increased half-life of c-Myc mRNA and blocked the cytostatic effect of TGF-beta1. Statistically significant correlations were observed between the single CpG site methylation and expression levels of TTP or c-Myc in clinical samples of HCC.

Conclusions: Abrogation of the post-transcriptional regulation of c-Myc via methylation of a specific single CpG site in the TTP promoter presents a novel mechanism for the gain of selective resistance to the antiproliferative signaling of TGF-beta1 in HCC.

Citing Articles

Tristetraprolin Family Members and Processing Bodies: A Complex Regulatory Network Involved in Fatty Liver Disease, Viral Hepatitis and Hepatocellular Carcinoma.

Gellee N, Legrand N, Jouve M, Devaux P, Dubuquoy L, Sobolewski C Cancers (Basel). 2025; 17(3).

PMID: 39941720 PMC: 11815756. DOI: 10.3390/cancers17030348.


Hepatitis B virus X protein and TGF-β: partners in the carcinogenic journey of hepatocellular carcinoma.

Yan W, Rao D, Fan F, Liang H, Zhang Z, Dong H Front Oncol. 2024; 14:1407434.

PMID: 38962270 PMC: 11220127. DOI: 10.3389/fonc.2024.1407434.


The Epigenetic Reader Methyl-CpG-Binding Protein 2 (MeCP2) Is an Emerging Oncogene in Cancer Biology.

Nejati-Koshki K, Roberts C, Babaei G, Rastegar M Cancers (Basel). 2023; 15(10).

PMID: 37345019 PMC: 10216337. DOI: 10.3390/cancers15102683.


Silencing lncRNA CDKN2B-AS1 Alleviates Childhood Asthma Progression Through Inhibiting ZFP36 Promoter Methylation and Promoting NR4A1 Expression.

Chen Z, Fan N, Shen G, Yang J Inflammation. 2022; 46(2):700-717.

PMID: 36422840 DOI: 10.1007/s10753-022-01766-2.


MicroRNAs, Tristetraprolin Family Members and HuR: A Complex Interplay Controlling Cancer-Related Processes.

Sobolewski C, Dubuquoy L, Legrand N Cancers (Basel). 2022; 14(14).

PMID: 35884580 PMC: 9319505. DOI: 10.3390/cancers14143516.